1. Introduction {#S9}
===============

1.1. Methodology and Evidence Review {#S10}
------------------------------------

The recommendations listed in this guideline are, whenever possible, evidence based. An initial extensive evidence review, which included literature derived from research involving human subjects, published in English, and indexed in MEDLINE (through PubMed), EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline, was conducted from January through September 2015. Key search words included but were not limited to the following: *acute limb ischemia, angioplasty, ankle-brachial index, anticoagulation, antiplatelet therapy, atypical leg symptoms, blood pressure lowering/hypertension, bypass graft/bypass grafting/surgical bypass, cilostazol, claudication/intermittent claudication, critical limb ischemia/severe limb ischemia, diabetes, diagnostic testing, endovascular therapy, exercise rehabilitation/exercise therapy/exercise training/ supervised exercise, lower extremity/foot wound/ulcer, peripheral artery disease/peripheral arterial disease/ peripheral vascular disease/lower extremity arterial disease, smoking/smoking cessation, statin, stenting, and vascular surgery*. Additional relevant studies published through September 2016, during the guideline writing process, were also considered by the writing committee, and added to the evidence tables when appropriate. The final evidence tables included in the [Online Data Supplement](#SD1){ref-type="supplementary-material"} summarize the evidence utilized by the writing committee to formulate recommendations. Additionally, the writing committee reviewed documents related to lower extremity PAD previously published by the ACC and AHA.^[@R10],[@R11]^ References selected and published in this document are representative and not all-inclusive.

As stated in the Preamble, the ACC/AHA guideline methodology provides for commissioning an independent ERC to address systematic review questions (PICOTS format) to inform recommendations developed by the writing committee. All other guideline recommendations (not based on the systematic review questions) were also subjected to an extensive evidence review process. For this guideline, the writing committee in conjunction with the Task Force and ERC Chair identified the following systematic review questions: 1) Is antiplatelet therapy beneficial for prevention of cardiovascular events in the patient with symptomatic or asymptomatic lower extremity PAD? 2) What is the effect of revascularization, compared with optimal medical therapy and exercise training, on functional outcome and quality of life (QoL) among patients with claudication? Each question has been the subject of recently published, systematic evidence reviews.^[@R12]--[@R14]^ The quality of these evidence reviews was appraised by the ACC/AHA methodologist and a vendor contracted to support this process (Doctor Evidence \[Santa Monica, CA\]). Few substantive randomized or nonrandomized studies had been published after the end date of the literature searches used for the existing evidence reviews, so the ERC concluded that no additional systematic review was necessary to address either of these critical questions.

A third systematic review question was then identified: 3) Is one revascularization strategy (endovascular or surgical) associated with improved cardiovascular and limb-related outcomes in patients with critical limb ischemia (CLI)? This question had also been the subject of a high-quality systematic review that synthesized evidence from observational data and an RCT^[@R15]^; additional RCTs addressing this question are ongoing.^[@R16]--[@R18]^ The writing committee and the Task Force decided to expand the survey to include more relevant randomized and observational studies. Based on evaluation of this additional evidence the ERC decided that further systematic review was not needed to inform the writing committee on this question. Hence, the ERC and writing committee concluded that available systematic reviews could be used to inform the development of recommendations addressing each of the 3 systematic review questions specified above. The members of the Task Force and writing committee thank the members of the ERC that began this process and their willingness to participate in this volunteer effort. They include Aruna Pradhan, MD, MPH (ERC Chair); Natalie Evans, MD; Peter Henke, MD; Dharam J. Kumbhani, MD, SM, FACC; and Tamar Polonsky, MD.

1.2. Organization of the Writing Committee {#S11}
------------------------------------------

The writing committee consisted of clinicians, including noninvasive and interventional cardiologists, exercise physiologists, internists, interventional radiologists, vascular nurses, vascular medicine specialists, and vascular surgeons, as well as clinical researchers in the field of vascular disease, a nurse (in the role of patient representative), and members with experience in epidemiology and/or health services research. The writing committee included representatives from the ACC and AHA, American Association of Cardiovascular and Pulmonary Rehabilitation, Inter-Society Consensus for the Management of Peripheral Arterial Disease, Society for Cardiovascular Angiography and Interventions, Society for Clinical Vascular Surgery, Society of Interventional Radiology, Society for Vascular Medicine, Society for Vascular Nursing, Society for Vascular Surgery, and Vascular and Endovascular Surgery Society.

1.3. Document Review and Approval {#S12}
---------------------------------

This document was reviewed by 2 official reviewers nominated by the ACC and AHA; 1 to 2 reviewers each from the American Association of Cardiovascular and Pulmonary Rehabilitation, Inter-Society Consensus for the Management of Peripheral Arterial Disease, Society for Cardiovascular Angiography and Interventions, Society for Clinical Vascular Surgery, Society of Interventional Radiology, Society for Vascular Medicine, Society for Vascular Nursing, Society for Vascular Surgery, and Vascular and Endovascular Surgery Society; and 16 additional individual content reviewers. Reviewers\' RWI information was distributed to the writing committee and is published in this document ([Appendix 2](#APP2){ref-type="app"}).

This document was approved for publication by the governing bodies of the ACC and the AHA and endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, Inter-Society Consensus for the Management of Peripheral Arterial Disease, Society for Cardiovascular Angiography and Interventions, Society for Clinical Vascular Surgery, Society of Interventional Radiology, Society for Vascular Medicine, Society for Vascular Nursing, Society for Vascular Surgery, and Vascular and Endovascular Surgery Society.

1.4. Scope of Guideline {#S13}
-----------------------

Lower extremity PAD is a common cardiovascular disease that is estimated to affect approximately 8.5 million Americans above the age of 40 years and is associated with significant morbidity, mortality, and QoL impairment.^[@R19]^ It has been estimated that 202 million people worldwide have PAD.^[@R20]^ The purpose of this document is to provide a contemporary guideline for diagnosis and management of patients with lower extremity PAD. This document supersedes recommendations related to lower extremity PAD in the "ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease"^[@R10]^ and the "2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease."^[@R11]^ The scope of this guideline is limited to atherosclerotic disease of the lower extremity arteries (PAD) and includes disease of the aortoiliac, femoropopliteal, and infrapopliteal arterial segments. It does not address nonatherosclerotic causes of lower extremity arterial disease, such as vasculitis, fibromuscular dysplasia, physiological entrapment syndromes, cystic adventitial disease, and other entities. Future guidelines will address aneurysmal disease of the abdominal aorta and lower extremity arteries and diseases of the renal and mesenteric arteries.

For the purposes of this guideline, key terms associated with PAD are defined in [Table 2](#T5){ref-type="table"}.

2. Clinical Assessment For Pad {#S14}
==============================

Evaluating the patient at increased risk of PAD ([Table 3](#T6){ref-type="table"}) begins with the clinical history, review of symptoms, and physical examination. The symptoms and signs of PAD are variable. Patients with PAD may experience the classic symptom of claudication or may present with advanced disease, including CLI. Studies have demonstrated that the majority of patients with confirmed PAD do not have typical claudication but have other non-joint-related limb symptoms (atypical leg symptoms) or are asymptomatic.^[@R40],[@R41]^ Patients with PAD who have atypical leg symptoms or no symptoms may have functional impairment comparable to patients with claudication.^[@R42]^ The vascular examination for PAD includes pulse palpation, auscultation for femoral bruits, and inspection of the legs and feet. Lower extremity pulses are assessed and rated as follows: 0, absent; 1, diminished; 2, normal; or 3, bounding. See [Table 4](#T7){ref-type="table"} for history and physical examination findings suggestive of PAD. To confirm the diagnosis of PAD, abnormal physical examination findings must be confirmed with diagnostic testing (Section 3), generally with the ankle-brachial index (ABI) as the initial test.

Patients with confirmed diagnosis of PAD are at increased risk for subclavian artery stenosis.^[@R43]--[@R45]^ An inter-arm blood pressure difference of \>15 to 20 mm Hg is abnormal and suggestive of subclavian (or innominate) artery stenosis. Measuring blood pressure in both arms identifies the arm with the highest systolic pressure, a requirement for accurate measurement of the ABI.^[@R46]^ Identification of unequal blood pressures in the arms also allows for more accurate measurement of blood pressure in the treatment of hypertension (ie, blood pressure is taken at the arm with higher measurements).

See [Online Data Supplements 1 and 2](#SD1){ref-type="supplementary-material"} for data supporting Section 2.

2.1. History and Physical Examination: Recommendations {#S15}
------------------------------------------------------

Recommendations for History and Physical Examination

COR

LOE

Recommendations

I

B-NR

Patients at increased risk of PAD (

Table 3

) should undergo a comprehensive medical history and a review of symptoms to assess for exertional leg symptoms, including claudication or other walking impairment, ischemic rest pain, and nonhealing wounds.

40

--

42

,

47

--

49

I

B-NR

Patients at increased risk of PAD (

Table 3

) should undergo vascular examination, including palpation of lower extremity pulses (ie, femoral, popliteal, dorsalis pedis, and posterior tibial), auscultation for femoral bruits, and inspection of the legs and feet.

48

,

50

,

51

I

B-NR

Patients with PAD should undergo noninvasive blood pressure measurement in both arms at least once during the initial assessment.

43

--

45

3. Diagnostic Testing For The Patient With Suspected Lower Extremity Pad (Claudication or Cli): Recommendations {#S16}
===============================================================================================================

History or physical examination findings suggestive of PAD need to be confirmed with diagnostic testing. The resting ABI is the initial diagnostic test for PAD and may be the only test required to establish the diagnosis and institute GDMT The resting ABI is a simple, noninvasive test that is obtained by measuring systolic blood pressures at the arms (brachial arteries) and ankles (dorsalis pedis and posterior tibial arteries) in the supine position by using a Doppler device. The ABI of each leg is calculated by dividing the higher of the dorsalis pedis pressure or posterior tibial pressure by the higher of the right or left arm blood pressure.^[@R46]^ Segmental lower extremity blood pressures and Doppler or plethysmographic waveforms (pulse volume recordings) are often performed along with the ABI and can be used to localize anatomic segments of disease (eg, aortoiliac, femoropopliteal, infrapopliteal).^[@R22],[@R53],[@R54]^

Depending on the clinical presentation (eg, claudication or CLI) and the resting ABI values, additional physiological testing studies may be indicated, including exercise treadmill ABI testing, measurement of the toe-brachial index (TBI), and additional perfusion assessment measures (eg, transcutaneous oxygen pressure \[TcPO~2~\], or skin perfusion pressure \[SPP\]). Exercise treadmill ABI testing is important to objectively measure functional limitations attributable to leg symptoms and is useful in establishing the diagnosis of lower extremity PAD in the symptomatic patient when resting ABIs are normal or borderline.^[@R54]--[@R59]^ The TBI is used to establish the diagnosis of PAD in the setting of non-compressible arteries (ABI \>1.40) and may also be used to assess perfusion in patients with suspected CLI. Studies for anatomic imaging assessment (duplex ultrasound, computed tomography angiography \[CTA\], or magnetic resonance angiography \[MRA\], invasive angiography) are generally reserved for highly symptomatic patients in whom revascularization is being considered. Depending on the modality, these studies may confer procedural risk.

See [Table 5](#T8){ref-type="table"} for alternative causes of leg pain in the patient with normal ABI and physiological testing; [Figure 1](#F1){ref-type="fig"} for the algorithm on diagnostic testing for suspected PAD and claudication; [Table 6](#T9){ref-type="table"} for alternative causes of nonhealing wounds in patients without PAD; [Figure 2](#F2){ref-type="fig"} for the algorithm on diagnostic testing for suspected CLI; and [Online Data Supplements 3 to 7](#SD1){ref-type="supplementary-material"} for data supporting Section 3.

3.1. Resting ABI for Diagnosing PAD {#S17}
-----------------------------------

Recommendations for Resting ABI for Diagnosing PAD

COR

LOE

Recommendations

I

B-NR

In patients with history or physical examination findings suggestive of PAD (

Table 4

), the resting ABI, with or without segmental pressures and waveforms, is recommended to establish the diagnosis.

60

--

65

I

C-LD

Resting ABI results should be reported as abnormal (ABI ≤0.90), borderline (ABI 0.91--0.99), normal (1.00--1.40), or noncompressible (ABI \>1.40).

46

,

63

--

66

IIa

B-NR

In patients at increased risk of PAD (

Table 3

) but without history or physical examination findings suggestive of PAD (

Table 4

), measurement of the resting ABI is reasonable.

41

,

42

,

67

--

89

III: No Benefit

B-NR

In patients not at increased risk of PAD (

Table 3

) and without history or physical examination findings suggestive of PAD (

Table 4

), the ABI is not recommended.

87

,

90

3.2. Physiological Testing {#S18}
--------------------------

Recommendations for Physiological Testing

COR

LOE

Recommendations

I

B-NR

Toe-brachial index (TBI) should be measured to diagnose patients with suspected PAD when the ABI is greater than 1.40.

66

,

91

--

94

I

B-NR

Patients with exertional non--joint-related leg symptoms and normal or borderline resting ABI (\>0.90 and ≤1.40) should undergo exercise treadmill ABI testing to evaluate for PAD.

54

--

59

IIa

B-NR

In patients with PAD and an abnormal resting ABI (≤0.90), exercise treadmill ABI testing can be useful to objectively assess functional status.

54

--

59

IIa

B-NR

In patients with normal (1.00--1.40) or borderline (0.91--0.99) ABI in the setting of nonhealing wounds or gangrene, it is reasonable to diagnose CLI by using TBI with waveforms, TcPO

2

, or SPP.

95

--

99

IIa

B-NR

In patients with PAD with an abnormal ABI (≤0.90) or with noncompressible arteries (ABI \>1.40 and TBI ≤0.70) in the setting of nonhealing wounds or gangrene, TBI with waveforms, TcPO

2

, or SPP can be useful to evaluate local perfusion.

95

--

99

3.3. Imaging for Anatomic Assessment {#S19}
------------------------------------

Recommendations for Imaging for Anatomic Assessment

COR

LOE

Recommendations

I

B-NR

Duplex ultrasound, CTA, or MRA of the lower extremities is useful to diagnose anatomic location and severity of stenosis for patients with symptomatic PAD in whom revascularization is considered.

100

--

103

I

C-EO

Invasive angiography is useful for patients with CLI in whom revascularization is considered.

IIa

C-EO

Invasive angiography is reasonable for patients with lifestyle-limiting claudication with an inadequate response to GDMT for whom revascularization is considered.

III: Harm

B-R

Invasive and noninvasive angiography (ie, CTA, MRA) should not be performed for the anatomic assessment of patients with asymptomatic PAD.

104

--

106

4. Screening For Atherosclerotic Disease In Other Vascular Beds For The Patient With Pad: Recommendations {#S20}
=========================================================================================================

See [Online Data Supplement 8](#SD1){ref-type="supplementary-material"} for data supporting Section 4.

4.1. Abdominal Aortic Aneurysm {#S21}
------------------------------

PAD has been recognized as a risk factor for abdominal aortic aneurysm (AAA). In observational studies, the prevalence of AAA (aortic diameter ≥3 cm) was higher in patients with symptomatic PAD than in the general population^[@R107],[@R108]^ and in a population of patients with atherosclerotic risk factors.^[@R109]^ The prevalence of AAA among patients with PAD increased with age, beginning in patients ≥55 years of age, and was highest in patients ≥75 years of age.^[@R107]^ There are no data on AAA screening in patients with asymptomatic PAD. This section refers to screening patients with symptomatic PAD for AAA. Recommendations for screening the general population with risk factors for AAA (based on age, sex, smoking history, and family history) have been previously published.^[@R10]^

Recommendation for Abdominal Aortic Aneurysm

COR

LOE

Recommendation

IIa

B-NR

A screening duplex ultrasound for AAA is reasonable in patients with symptomatic PAD.

107

--

109

4.2. Screening for Asymptomatic Atherosclerosis in Other Arterial Beds (Coronary, Carotid, and Renal Arteries) {#S22}
--------------------------------------------------------------------------------------------------------------

The prevalence of atherosclerosis in the coronary, carotid, and renal arteries is higher in patients with PAD than in those without PAD.^[@R109]--[@R115]^ However, intensive atherosclerosis risk factor modification in patients with PAD is justified regardless of the presence of disease in other arterial beds. Thus, the only justification for screening for disease in other arterial beds is if revascularization results in a reduced risk of myocardial infarction (MI), stroke, or death, and this has never been shown. Currently, there is no evidence to demonstrate that screening all patients with PAD for asymptomatic atherosclerosis in other arterial beds improves clinical outcome. Intensive treatment of risk factors through GDMT is the principle method for preventing adverse cardiovascular ischemic events from asymptomatic disease in other arterial beds.

5. Medical Therapy For The Patient With Pad: Recommendations {#S23}
============================================================

Patients with PAD should receive a comprehensive program of GDMT, including structured exercise and lifestyle modification, to reduce cardiovascular ischemic events and improve functional status. Smoking cessation is a vital component of care for patients with PAD who continue to smoke. A guideline-based program of pharmacotherapy to reduce cardiovascular ischemic events and limb-related events should be prescribed for each patient with PAD and is customized to individual risk factors, such as whether the patient also has diabetes mellitus. Pharmacotherapy for the patient with PAD includes antiplatelet and statin agents and is customized to additional risk factors, such as whether the patient also has diabetes mellitus or hypertension. Previous studies have demonstrated that patients with PAD are less likely to receive GDMT than patients with other forms of cardiovascular disease, including coronary artery disease.^[@R116]--[@R118]^ Cilostazol is an effective medical therapy for treatment of leg symptoms and walking impairment due to claudication.^[@R119]^ However, side effects include headache, diarrhea, dizziness, and palpitations and in 1 trial, 20% of patients discontinued cilostazol within 3 months.^[@R120]^

See Online Data Supplements 13 to 19 for data supporting Section 5.

5.1. Antiplatelet, Statin, Antihypertensive Agents, and Oral Anticoagulation {#S24}
----------------------------------------------------------------------------

Recommendations for Antiplatelet, Statin, and Antihypertensive Agents

COR

LOE

Recommendations

Antiplatelet Agents

I

A

Antiplatelet therapy with aspirin alone (range 75--325 mg per day) or clopidogrel alone (75 mg per day) is recommended to reduce MI, stroke, and vascular death in patients with symptomatic PAD.

121

--

124

IIa

C-EO

In asymptomatic patients with PAD (ABI ≤0.90), antiplatelet therapy is reasonable to reduce the risk of MI, stroke, or vascular death.

IIb

B-R

In asymptomatic patients with borderline ABI (0.91--0.99), the usefulness of antiplatelet therapy to reduce the risk of MI, stroke, or vascular death is uncertain.

67

,

68

IIb

B-R

The effectiveness of dual antiplatelet therapy (aspirin and clopidogrel) to reduce the risk of cardiovascular ischemic events in patients with symptomatic PAD is not well established.

125

,

126

IIb

C-LD

Dual antiplatelet therapy (aspirin and clopidogrel) may be reasonable to reduce the risk of limb-related events in patients with symptomatic PAD after lower extremity revascularization.

127

--

130

IIb

B-R

The overall clinical benefit of vorapaxar added to existing antiplatelet therapy in patients with symptomatic PAD is uncertain.

131

--

134

Statin Agents

I

A

Treatment with a statin medication is indicated for all patients with PAD.

88

,

135

--

139

Antihypertensive Agents

I

A

Antihypertensive therapy should be administered to patients with hypertension and PAD to reduce the risk of MI, stroke, heart failure, and cardiovascular death.

140

--

144

IIa

A

The use of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers can be effective to reduce the risk of cardiovascular ischemic events in patients with PAD.

143

,

145

,

146

Oral Anticoagulation

IIb

B-R

The usefulness of anticoagulation to improve patency after lower extremity autogenous vein or prosthetic bypass is uncertain.

147

--

149

III: Harm

A

Anticoagulation should not be used to reduce the risk of cardiovascular ischemic events in patients with PAD.

148

,

150

--

152

5.2. Smoking Cessation {#S25}
----------------------

Recommendations for Smoking Cessation

COR

LOE

Recommendations

I

A

Patients with PAD who smoke cigarettes or use other forms of tobacco should be advised at every visit to quit.

153

--

155

I

A

Patients with PAD who smoke cigarettes should be assisted in developing a plan for quitting that includes pharmacotherapy (ie, varenicline, bupropion, and/or nicotine replacement therapy) and/or referral to a smoking cessation program.

153

,

156

--

158

I

B-NR

Patients with PAD should avoid exposure to environmental tobacco smoke at work, at home, and in public places.

159

,

160

5.3. Glycemic Control {#S26}
---------------------

Recommendations for Glycemic Control

COR

LOE

Recommendations

I

C-EO

Management of diabetes mellitus in the patient with PAD should be coordinated between members of the healthcare team.

IIa

B-NR

Glycemic control can be beneficial for patients with CLI to reduce limb-related outcomes

161

,

162

5.4. Cilostazol, Pentoxifylline, and Chelation Therapy {#S27}
------------------------------------------------------

Recommendations for Cilostazol, Pentoxifylline, and Chelation Therapy

COR

LOE

Recommendations

I

A

Cilostazol is an effective therapy to improve symptoms and increase walking distance in patients with claudication.

119

,

163

III: No Benefit

B-R

Pentoxifylline is not effective for treatment of claudication.

119

,

164

III: No Benefit

B-R

Chelation therapy (eg, ethylenediaminetetraacetic acid) is not beneficial for treatment of claudication.

165

5.5. Homocysteine Lowering {#S28}
--------------------------

Recommendation for Homocysteine Lowering

COR

LOE

Recommendation

III: No Benefit

B-R

B-complex vitamin supplementation to lower homocysteine levels for prevention of cardiovascular events in patients with PAD is not recommended.

166

--

168

5.6. Infuenza Vaccination {#S29}
-------------------------

Recommendation for Influenza Vaccination

COR

LOE

Recommendation

I

C-EO

Patients with PAD should have an annual influenza vaccination.

6. Structured Exercise Therapy: Recommendations {#S30}
===============================================

Structured exercise therapy is an important element of care for the patient with PAD. Components of structured exercise programs for PAD are outlined in [Table 7](#T10){ref-type="table"}. The data supporting the efficacy of supervised exercise programs as an initial treatment for claudication continue to develop and remain convincing, building on many earlier RCTs.^[@R28]--[@R34],[@R36],[@R169],[@R170]^ Trials with long-term follow-up from 18 months^[@R25],[@R26]^ to 7 years^[@R24]^ have demonstrated a persistent benefit of supervised exercise in patients with claudication. The risk--benefit ratio for supervised exercise in PAD is favorable, with an excellent safety profile in patients screened for absolute contraindications to exercise such as exercise-limiting cardiovascular disease, amputation or wheelchair confinement, and other major comorbidities that would preclude exercise.^[@R24],[@R27],[@R37],[@R171]--[@R174]^

Studies supporting structured community- or home-based programs for patients with PAD are more recent than studies supporting supervised exercise programs and have provided strong evidence in support of the community- or home-based approach.^[@R35],[@R37],[@R39],[@R80],[@R86],[@R171]^ Unstructured community- or home-based walking programs that consist of providing general recommendations to patients with claudication to simply walk more are not efficacious.^[@R38]^

See [Online Data Supplements 32 and 33](#SD1){ref-type="supplementary-material"} for data supporting Section 6.

Recommendations for Structured Exercise Therapy

COR

LOE

Recommendations

I

A

In patients with claudication, a supervised exercise program is recommended to improve functional status and QoL and to reduce leg symptoms.

24

--

26

,

28

--

34

,

36

,

169

,

170

I

B-R

A supervised exercise program should be discussed as a treatment option for claudication before possible revascularization.

24

--

26

IIa

A

In patients with PAD, a structured community-or home-based exercise program with behavioral change techniques can be beneficial to improve walking ability and functional status.

37

,

80

,

86

,

171

IIa

A

In patients with claudication, alternative strategies of exercise therapy, including upper-body ergometry, cycling, and pain-free or low-intensity walking that avoids moderate-to-maximum claudication while walking, can be beneficial to improve walking ability and functional status.

27

,

173

,

175

,

176

7. Minimizing Tissue Loss In Patients With Pad: Recommendations {#S31}
===============================================================

Prevention of wounds through patient education, foot examination, and prompt recognition of foot infection is important to minimize tissue loss among patients with PAD. Education includes teaching patients about healthy foot behaviors (eg, daily inspection of feet, wearing of shoes and socks; avoidance of barefoot walking), the selection of proper footwear, and the importance of seeking medical attention for new foot problems.^[@R177]^ Educational efforts are especially important for patients with PAD who have diabetes mellitus with peripheral neuropathy.

Foot infections (infection of any of the structures distal to the malleoli) may include cellulitis, abscess, fasciitis, tenosynovitis, septic joint space infection, and osteomyelitis. Because of the consequences associated with untreated foot infection---especially in the presence of PAD---clinicians should maintain a high index of suspicion.^[@R178]^ Foot infection is suspected if the patient presents with local pain or tenderness; periwound erythema; periwound edema, induration, or fluctuance; pretibial edema; any discharge (especially purulent); foul odor; visible bone or a wound that probes to bone; or signs of a systemic inflammatory response (including temperature \>38°C or \<36°C, heart rate \>90/min, respiratory rate \>20/min or Paco~2~ \<32 mm Hg, white blood cell count \>12 000 or \<4000/mcL or \>10% immature forms).^[@R179]^ It is recognized that the presence of diabetes mellitus with peripheral neuropathy and PAD may make the presentation of foot infection more subtle than in patients without these problems.

See [Online Data Supplement 34](#SD1){ref-type="supplementary-material"} for data supporting Section 7.

Recommendations for Minimizing Tissue Loss in Patients With PAD

COR

LOE

Recommendations

I

C-LD

Patients with PAD and diabetes mellitus should be counseled about self--foot examination and healthy foot behaviors.

177

,

180

I

C-LD

In patients with PAD, prompt diagnosis and treatment of foot infection are recommended to avoid amputation.

178

,

179

,

181

--

183

IIa

C-LD

In patients with PAD and signs of foot infection, prompt referral to an interdisciplinary care team (

Table 8

) can be beneficial.

178

,

184

,

185

IIa

C-EO

It is reasonable to counsel patients with PAD without diabetes mellitus about self--foot examination and healthy foot behaviors.

IIa

C-EO

Biannual foot examination by a clinician is reasonable for patients with PAD and diabetes mellitus.

8. Revascularization For Claudication: Recommendations {#S32}
======================================================

A minority of patients with claudication (estimated at \<10% to 15% over 5 years or more) will progress to CLI.^[@R186]--[@R189]^ Therefore, the role of revascularization in claudication is improvement in claudication symptoms and functional status, and consequently in QoL, rather than limb salvage. Revascularization is reasonable when the patient who is being treated with GDMT (including structured exercise therapy) presents with persistent lifestyle-limiting claudication.^[@R13],[@R25],[@R26],[@R190],[@R191]^ Lifestyle-limiting claudication is defined by the patient rather than by any test. It includes impairment of activities of daily living and/or vocational and/or recreational activities due to claudication. An individualized approach to revascularization for claudication is recommended for each patient to optimize outcome. Revascularization is but one component of care for the patient with claudication, inasmuch as each patient should have a customized care plan that also includes medical therapy (Section 5), structured exercise therapy (Section 6), and care to minimize tissue loss (Section 7). If a strategy of revascularization for claudication is undertaken, the revascularization strategy should be evidence based and can include endovascular revascularization, surgery, or both.

Due to the variability of ischemic limb symptoms and impact of these symptoms on functional status and QoL, patients should be selected for revascularization on the basis of severity of their symptoms. Factors to consider include a significant disability as assessed by the patient, adequacy of response to medical and structured exercise therapy, status of comorbid conditions, and a favorable risk--benefit ratio. Patient preferences and goals of care are important considerations in the evaluation for revascularization. The revascularization strategy should have a reasonable likelihood of providing durable relief of symptoms. There should be clear discussion with the patient about expected risks and benefits of revascularization, as well as discussion of the durability of proposed procedures. A general recommendation for revascularization as a treatment option for claudication is provided below followed by specific recommendations for endovascular (Section 8.1.1) and surgical (Section 8.1.2) procedures if a revascularization strategy is undertaken.

See [Online Data Supplements 35 to 38](#SD1){ref-type="supplementary-material"} for data supporting Section 8.

8.1. Revascularization for Claudication {#S33}
---------------------------------------

Recommendation for Revascularization for Claudication

COR

LOE

Recommendation

IIa

A

Revascularization is a reasonable treatment option for the patient with lifestyle-limiting claudication with an inadequate response to GDMT.

13

,

25

,

26

,

190

,

191

### 8.1.1. Endovascular Revascularization for Claudication {#S34}

Endovascular techniques to treat claudication include balloon dilation (angioplasty), stents, and atherectomy. These techniques continue to involve and now include covered stents, drug-eluting stents, cutting balloons, and drug-coated balloons. The technique chosen for endovascular treatment is related to lesion characteristics (eg, anatomic location, lesion length, degree of calcification) and operator experience. Assessment of the appropriateness of specific endovascular techniques for specific lesions for the treatment of claudication is beyond the scope of this document.

Revascularization is performed on lesions that are deemed to be hemodynamically significant, and stenoses selected for endovascular treatment should have a reasonable likelihood of limiting perfusion to the distal limb. Stenoses of 50% to 75% diameter by angiography may not be hemodynamically significant, and resting or provoked intravascular pressure measurements may be used to determine whether lesions are significant.^[@R192],[@R193]^ Multiple RCTs have compared endovascular procedures to various combinations of medical treatment with or without supervised or unsupervised exercise programs.^[@R13],[@R25],[@R26],[@R190],[@R191],[@R194]--[@R206]^ These trials have used different endpoints and enrolled patients with anatomic disease distribution at different levels. Long-term patency is greater in the aortoiliac than in the femoropopliteal segment. Furthermore, for femoropopliteal disease, durability is diminished with greater lesion length, occlusion rather than stenosis, the presence of multiple and diffuse lesions, poor-quality runoff, diabetes mellitus, chronic kidney disease, renal failure, and smoking.^[@R207]--[@R210]^

Recommendations for Endovascular Revascularization for Claudication

COR

LOE

Recommendations

I

A

Endovascular procedures are effective as a revascularization option for patients with lifestyle-limiting claudication and hemodynamically significant aortoiliac occlusive disease.

13

,

25

,

26

,

190

,

194

,

196

,

201

IIa

B-R

Endovascular procedures are reasonable as a revascularization option for patients with lifestyle-limiting claudication and hemodynamically significant femoropopliteal disease.

190

,

197

--

200

,

205

,

206

IIb

C-LD

The usefulness of endovascular procedures as a revascularization option for patients with claudication due to isolated infrapopliteal artery disease is unknown.

211

--

213

III: Harm

B-NR

Endovascular procedures should not be performed in patients with PAD solely to prevent progression to CLI.

186

--

189

,

214

--

216

### 8.1.2. Surgical Revascularization for Claudication {#S35}

Systematic reviews have concluded that surgical procedures are an effective treatment for claudication and have a positive impact on QoL and walking parameters but have identified sparse evidence supporting the effectiveness of surgery compared with other treatments.^[@R12],[@R191],[@R217],[@R218]^ Although symptom and patency outcomes for surgical interventions may be superior to those for less invasive endovascular treatments, surgical interventions are also associated with greater risk of adverse perioperative events^[@R219]--[@R225]^ Treatment selection should therefore be individualized on the basis of the patient\'s goals, perioperative risk, and anticipated benefit. Surgical procedures for claudication are usually reserved for individuals who a) do not derive adequate benefit from nonsurgical therapy, b) have arterial anatomy favorable to obtaining a durable result with surgery, and c) have acceptable risk of perioperative adverse events. Acceptable risk is defined by the individual patient and provider on the basis of symptom severity, comorbid conditions, and appropriate GDMT risk evaluation.

The superficial femoral and proximal popliteal arteries are the most common anatomic sites of stenosis or occlusion among individuals with claudication. Femoral-popliteal bypass is therefore one of the most common surgical procedures for claudication. The type of conduit and site of popliteal artery anastomosis (above versus below knee) are major determinants of outcomes associated with femoral-popliteal bypass. Systematic reviews and meta-analyses have identified a clear and consistent primary patency benefit for autogenous vein versus prosthetic grafts for popliteal artery bypass.^[@R226],[@R227]^

Recommendations for Surgical Revascularization for Claudication

COR

LOE

Recommendations

I

A

When surgical revascularization is performed, bypass to the popliteal artery with autogenous vein is recommended in preference to prosthetic graft material.

226

--

234

IIa

B-NR

Surgical procedures are reasonable as a revascularization option for patients with lifestyle-limiting claudication with inadequate response to GDMT, acceptable perioperative risk, and technical factors suggesting advantages over endovascular procedures.

190

,

230

,

235

--

237

III: Harm

B-R

Femoral-tibial artery bypasses with prosthetic graft material should not be used for the treatment of claudication.

238

--

240

III: Harm

B-NR

Surgical procedures should not be performed in patients with PAD solely to prevent progression to CLI.

186

--

189

,

241

9. Management Of Cli: Recommendations {#S36}
=====================================

Patients with CLI are at increased risk of amputation and major cardiovascular ischemic events. Care of the patient with CLI includes evaluation for revascularization and wound healing therapies, with the objective to minimize tissue loss, completely heal wounds, and preserve a functional foot. Medical therapy to prevent cardiovascular ischemic events is also an important component of care for the patient with CLI (Section 5).

See [Online Data Supplements 39 and 40](#SD1){ref-type="supplementary-material"} for data supporting Section 9.

9.1. Revascularization for CLI {#S37}
------------------------------

The goal of surgical or endovascular revascularization in CLI is to provide in-line blood flow to the foot through at least 1 patent artery, which will help decrease ischemic pain and allow healing of any wounds, while preserving a functional limb. The BASIL (Bypass versus Angioplasty in Severe Ischemia of the Leg) RCT^[@R242],[@R243]^ demonstrated that endovascular revascularization is an effective option for patients with CLI as compared with open surgery. The primary endpoint of amputation-free survival was the same in the endovascular and surgical arms. Of note, the endovascular arm used only percutaneous transluminal angioplasty.^[@R242],[@R243]^ Multiple RCTs comparing contemporary surgical and endovascular treatment for patients with CLI are ongoing.^[@R16]--[@R18]^ [Table 9](#T12){ref-type="table"} addresses factors that may prompt an endovascular versus surgical approach to the patient with CLI.

The angiosome concept has been described in the literature and entails establishing direct blood flow to the infrapopliteal artery directly responsible for perfusing the region of the leg or foot with the nonhealing wound. Multiple retrospective studies and 1 small nonrandomized prospective study assessing the efficacy of this concept have been published.^[@R245]--[@R257]^ Meta-analyses of these studies found improved wound healing and limb salvage with angiosome-guided therapy but cautioned that the quality of the evidence was low.^[@R258],[@R259]^ Although the angiosome concept is theoretically satisfying, randomized data comparing the establishment of in-line flow versus angiosome-guided therapy have yet to be published. Furthermore, there is no evidence yet to demonstrate the potential benefit of treating additional infrapopliteal arteries once in-line flow has been established in one artery, regardless of angiosome.

Recommendation for Revascularizations for CLI

COR

LOE

Recommendation

I

B-NR

In patients with CLI, revascularization should be performed when possible to minimize tissue loss.

260

I

C-EO

An evaluation for revascularization options should be performed by an interdisciplinary care team (

Table 8

) before amputation in the patient with CLI.

### 9.1.1. Endovascular Revascularization for CLI {#S38}

Recommendations for Endovascular Revascularization for CLI

COR

LOE

Recommendations

I

B-R

Endovascular procedures are recommended to establish in-line blood flow to the foot in patients with nonhealing wounds or gangrene.

242

,

243

IIa

C-LD

A staged approach to endovascular procedures is reasonable in patients with ischemic rest pain.

261

,

262

IIa

B-R

Evaluation of lesion characteristics can be useful in selecting the endovascular approach for CLI.

263

,

264

IIb

B-NR

Use of angiosome-directed endovascular therapy may be reasonable for patients with CLI and nonhealing wounds or gangrene.

245

,

247

--

249

,

251

--

253

,

255

--

257

### 9.1.2. Surgical Revascularization for CLI {#S39}

Recommendations for Surgical Revascularization for CLI

COR

LOE

Recommendations

I

A

When surgery is performed for CLI, bypass to the popliteal or infrapopliteal arteries (ie, tibial, pedal) should be constructed with suitable autogenous vein.

228

,

231

,

234

,

265

I

C-LD

Surgical procedures are recommended to establish in-line blood flow to the foot in patients with nonhealing wounds or gangrene.

266

--

268

IIa

B-NR

In patients with CLI for whom endovascular revascularization has failed and a suitable autogenous vein is not available, prosthetic material can be effective for bypass to the below-knee popliteal and tibial arteries.

269

--

271

IIa

C-LD

A staged approach to surgical procedures is reasonable in patients with ischemic rest pain.

272

--

274

9.2. Wound Healing Therapies for CLI {#S40}
------------------------------------

A comprehensive plan for treatment of CLI includes a plan to achieve an intact skin surface on a functional foot. The management of patients with CLI and nonhealing wounds includes coordinated efforts for both revascularization and wound healing among members of an interdisciplinary care team ([Table 8](#T11){ref-type="table"}). The structure and activities of interdisciplinary care teams for CLI may vary according to several factors, including the local availability of resources. Revascularization is coordinated with the efforts of clinicians who manage foot infections, provide offloading, and achieve complete wound healing, either through medical therapy, surgical options, or a combination of these options.

See [Online Data Supplement 34a](#SD1){ref-type="supplementary-material"} for a complete list of functions of the interdisciplinary care team.

Recommendations for Wound Healing Therapies for CLI

COR

LOE

Recommendations

I

B-NR

An interdisciplinary care team should evaluate and provide comprehensive care for patients with CLI and tissue loss to achieve complete wound healing and a functional foot.

184

,

275

--

277

I

C-LD

In patients with CLI, wound care after revascularization should be performed with the goal of complete wound healing.

275

IIb

B-NR

In patients with CLI, intermittent pneumatic compression (arterial pump) devices may be considered to augment wound healing and/or ameliorate severe ischemic rest pain.

278

IIb

C-LD

In patients with CLI, the effectiveness of hyperbaric oxygen therapy for wound healing is unknown.

279

III: No Benefit

B-R

Prostanoids are not indicated in patients with CLI.

280

10. Management Of Acute Limb Ischemia: Recommendations {#S41}
======================================================

Acute limb ischemia (ALI) is one of the most treatable and potentially devastating presentations of PAD. Timely recognition of arterial occlusion as the cause of an ischemic, cold, painful leg is crucial to successful treatment. The writing committee has used a standard definition of ALI in which symptom duration is \<2 weeks ([Table 2](#T5){ref-type="table"}).^[@R21],[@R22]^ Category I refers to viable limbs that are not immediately threatened. Category II refers to threatened limbs. Category IIa limbs are marginally threatened and salvageable, if promptly treated. Category IIb are immediately threatened limbs that require immediate revascularization if salvage is to be accomplished. Category III are irreversibly damaged limbs, in which case resultant major tissue loss or permanent nerve damage is inevitable.^[@R22]^

Patients with ALI should be rapidly evaluated by a vascular specialist if one is available. Depending on local clinical expertise, the vascular specialist may be a vascular surgeon, interventional radiologist, cardiologist, or a general surgeon with specialized training and experience in treating PAD. If such expertise is not locally or rapidly available, there should be strong consideration of transfer of the patient to a facility with such resources. The more advanced the degree of ischemia, the more rapidly the communication (eg, with regard to potential patient transfer) needs to occur.

ALI is a medical emergency and must be recognized rapidly. The time constraint is due to the period that skeletal muscle will tolerate ischemia---roughly 4 to 6 hours.^[@R281]^ A rapid assessment of limb viability and ability to restore arterial blood flow should be performed by a clinician able to either complete the revascularization or triage the patient.^[@R282]^ Lower extremity symptoms in ALI can include both pain and loss of function. The longer these symptoms are present, the less likely the possibility of limb salvage.^[@R283],[@R284]^ Clinical assessment must include symptom duration, pain intensity, and motor and sensory deficit severity to distinguish a threatened from a nonviable extremity ([Figure 3](#F3){ref-type="fig"}). The bedside assessment includes arterial and venous examination with a handheld continuous-wave Doppler because of the inaccuracy of pulse palpation.^[@R22]^ The loss of Dopplerable arterial signal indicates that the limb is threatened. The absence of both arterial and venous Doppler signal indicates that the limb may be irreversibly damaged (nonsalvageable). Comorbidities should be investigated and managed aggressively, but this must not delay therapy. Even in the setting of rapid and effective revascularization, the 1-year morbidity and mortality rates ALI are high.^[@R283],[@R285]^

See [Figure 3](#F3){ref-type="fig"} for the algorithm on diagnosis and management of ALI and [Online Data Supplements 45 to 50](#SD1){ref-type="supplementary-material"} for data supporting Section 10.

10.1. Clinical Presentation of ALI {#S42}
----------------------------------

Recommendations for Clinical Presentation of ALI

COR

LOE

Recommendations

I

C-EO

Patients with ALI should be emergently evaluated by a clinician with sufficient experience to assess limb viability and implement appropriate therapy.

I

C-LD

In patients with suspected ALI, initial clinical evaluation should rapidly assess limb viability and potential for salvage and does not require imaging.

282

--

284

,

286

,

287

10.2. Medical Therapy for ALI {#S43}
-----------------------------

Recommendation for ALI Medical Therapy

COR

LOE

Recommendation

I

C-EO

In patients with ALI, systemic anticoagulation with heparin should be administered unless contraindicated.

10.3. Revascularization for ALI {#S44}
-------------------------------

For marginally or immediately threatened limbs (Category IIa and IIb ALI), revascularization should be performed emergently (within 6 hours). For viable limbs (Category I ALI), revascularization should be performed an on urgent basis (within 6--24 hours). The revascularization strategy can range from catheter-directed thrombolysis to surgical thromboembolectomy. Available facilities and clinical expertise are factors that should be considered when determining the revascularization strategy. The technique that will provide the most rapid restoration of arterial flow with the least risk to the patient should be selected. For example, catheter-directed thrombolysis can provide rapid restoration of arterial flow to a viable or marginally threatened limb, particularly in the setting of recent occlusion, thrombosis of synthetic grafts, and stent thrombosis.^[@R288]^ If this is not available locally, surgical options for timely revascularization should be considered, along with the feasibility of timely transfer to a facility with the necessary expertise.

Prolonged duration of ischemia is the most common factor in patients requiring amputation for treatment of ALI. The risks associated with reconstruction outweigh the potential benefit in a limb that is already insensate or immobile because of prolonged ischemia. Patients who have an insensate and immobile limb in the setting of prolonged ischemia (\>6 to 8 hours) are unlikely to have potential for limb salvage with revascularization.

Recommendations for Revascularization for ALI

COR

LOE

Recommendations

I

C-LD

In patients with ALI, the revascularization strategy should be determined by local resources and patient factors (eg, etiology and degree of ischemia).

288

--

290

I

A

Catheter-based thrombolysis is effective for patients with ALI and a salvageable limb.

288

--

292

I

C-LD

Amputation should be performed as the first procedure in patients with a nonsalvageable limb.

293

,

294

I

C-LD

Patients with ALI should be monitored and treated (eg, fasciotomy) for compartment syndrome after revascularization.

293

,

294

IIa

B-NR

In patients with ALI with a salvageable limb, percutaneous mechanical thrombectomy can be useful as adjunctive therapy to thrombolysis.

295

--

299

IIa

C-LD

In patients with ALI due to embolism and with a salvageable limb, surgical thromboembolectomy can be effective.

300

--

302

IIb

C-LD

The usefulness of ultrasound-accelerated catheter-based thrombolysis for patients with ALI with a salvageable limb is unknown.

303

--

305

10.4. Diagnostic Evaluation of the Cause of ALI {#S45}
-----------------------------------------------

ALI may be related to underlying PAD (including prior lower extremity bypass graft) or may be related to other conditions that can result in ALI through either thrombotic (eg, hypercoagulable state) or embolic mechanisms. Treatment of ALI should not be delayed for testing for the underlying cause of the limb ischemia because delay from symptom onset to revascularization is a major determinant of outcome.^[@R283],[@R284]^ The evaluation of a cardiovascular (ie, embolic) cause for ALI is most useful in the patient without underlying PAD and can be completed after revascularization. Evaluation for cardiovascular cause includes electrocardiogram or additional heart rhythm monitoring to detect atrial fibrillation, electrocardiogram to detect evidence of MI, and echocardiography to further determine whether there is a cardiac etiology for thromboembolism, such as valvular vegetation, left atrial or left ventricular thrombus, or intracardiac shunt.

Recommendations for Diagnostic Evaluation of the Cause of ALI

COR

LOE

Recommendations

I

C-EO

In the patient with ALI, a comprehensive history should be obtained to determine the cause of thrombosis and/or embolization.

IIa

C-EO

In the patient with a history of ALI, testing for a cardiovascular cause of thromboembolism can be useful.

11. Longitudinal Follow-Up: Recommendations {#S46}
===========================================

PAD is a lifelong chronic medical condition. A comprehensive care plan for patients with PAD includes periodic clinical evaluation by a healthcare provider with experience in the care of vascular patients. Ongoing care focuses on cardiovascular risk reduction with medical therapy, optimizing functional status with structured exercise, and, when indicated, revascularization. The care plan is further customized depending on whether the patient has undergone a revascularization procedure.

See [Online Data Supplements 51 and 52](#SD1){ref-type="supplementary-material"} for data supporting Section 11.

Recommendations for Longitudinal Follow-Up

COR

LOE

Recommendations

I

C-EO

Patients with PAD should be followed up with periodic clinical evaluation, including assessment of cardiovascular risk factors, limb symptoms, and functional status.

I

C-EO

Patients with PAD who have undergone lower extremity revascularization (surgical and/or endovascular) should be followed up with periodic clinical evaluation and ABI measurement.

IIa

B-R

Duplex ultrasound can be beneficial for routine surveillance of infrainguinal, autogenous vein bypass grafts in patients with PAD.

306

--

312

IIa

C-LD

Duplex ultrasound is reasonable for routine surveillance after endovascular procedures in patients with PAD.

313

--

315

IIb

B-R

The effectiveness of duplex ultrasound for routine surveillance of infrainguinal prosthetic bypass grafts in patients with PAD is uncertain.

310

,

316

--

318

12. Evidence Gaps and Future Research Directions {#S47}
================================================

In performing the evidence review and in developing the present guidelines, the writing committee identified the following critical evidence gaps and future directions for PAD-related research: Basic science and translational studies to better understand the vascular biology of endovascular therapies and bypass grafting and to develop new methods for preventing restenosis after revascularization.Determination of risk factors for progression from asymptomatic PAD to symptomatic disease, including CLI.RCTs needed to determine the value of using the ABI to identify asymptomatic patients with PAD for therapies to reduce cardiovascular risk (eg, antiplatelet agents, statins, and other therapies).Advancement in PAD diagnostics, such as technologies for simplified yet highly accurate measurement of the ABI and tools for more reliable noninvasive perfusion assessment in CLI.Comparative-effectiveness studies to determine the optimal antiplatelet therapy (drug or drugs and dosage) for prevention of cardiovascular and limb-related events in patients with PAD.Development of additional medical therapies for claudication---an area of unmet medical need with a currently limited research pipeline.^[@R319]^Studies to investigate the role of dietary intervention, in addition to statin therapy, to improve outcome and modify the natural history of PAD.Additional research to identify the best community-or home-based exercise programs for patients with PAD to maximize functional status and improve QoL, as well as the role of such exercise programs before or in addition to revascularization.Development and validation of improved clinical classification systems for PAD that incorporate symptoms, anatomic factors, and patient-specific risk factors and can be used to predict clinical outcome and optimize treatment approach. An example of a recently developed classification system is the Society for Vascular Surgery limb classification system, based on wound, ischemia, and foot infection (WIfI), which has been validated in different populations and may permit more meaningful prognosis in patients with CLI.^[@R320]--[@R324]^Comparative- and cost-effectiveness studies of the different endovascular technologies for treatment of claudication and CLI, including drug-coated balloons and drug-eluting stents. Studies should include patient-centered endpoints, such as functional parameters, time to wound healing, and QoL, in addition to standard patency-focused outcomes. These studies could then be incorporated into value-based clinical algorithms for approach to revascularization for claudication and CLI.Additional studies to demonstrate the impact of multisocietal registries on clinical outcomes and appropriate use. At present, these include: the Vascular Quality Initiative (VQI), the National Cardiovascular Data Registry Peripheral Vascular Intervention Registry™ (PVI Registry™), and the National Radiology Data Registry for Interventional Radiology (NRDR). These registries provide an opportunity to obtain "real-world" data on surgical and endovascular procedures for PAD and improve quality by providing feedback to participating centers. Future efforts should incorporate these registries into interventional RCTs and post-marketing studies of PAD-related devices.

13. Advocacy Priorities {#S48}
=======================

The writing committee identified 3 priorities for multisocietal advocacy initiatives to improve health care for patients with PAD. First, the writing committee supports the availability of the ABI as the initial diagnostic test to establish the diagnosis of PAD in patients with history or physical examination findings suggestive of PAD ([Table 4](#T7){ref-type="table"}). Although the ABI test is generally reimbursed by third-party payers for patients with classical claudication or lower extremity wounds, payers may not provide reimbursement for the ABI with other findings suggestive of PAD, such as lower extremity pulse abnormalities or femoral bruits. The writing committee affirms the importance of confirming the diagnosis of PAD in such patients to allow for GDMT as delineated in this document. Second, the writing committee supports the vital importance of insuring access to supervised exercise programs for patients with PAD. Although extensive high-quality evidence supports supervised exercise programs to improve functional status and QoL, only a minority of patients with PAD participate in such programs because of lack of reimbursement by third-party payers. Third, the writing committee recognizes the need for incorporation of patient-centered outcomes into the process of regulatory approval of new medical therapies and revascularization technologies. For revascularization technologies, regulatory approval is driven primarily by data on angiographic efficacy (ie, target-lesion patency) and safety endpoints. The nature of the functional limitation associated with PAD warrants the incorporation of patient-centered outcomes, such as functional parameters and QoL, into the efficacy outcomes for the approval process.
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======================
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###### Abbreviations

  --------------------------------------------------
  AAA = abdominal aortic aneurysm
  ABI = ankle-brachial index
  ALI = acute limb ischemia
  CLI = critical limb ischemia
  GDMT = guideline-directed management and therapy
  MRA = magnetic resonance angiography
  PAD = peripheral artery disease
  RCT = randomized controlled trial
  SPP = skin perfusion pressure
  TBI = toe-brachial index
  TcPO~2~ = transcutaneous oxygen pressure
  QoL = quality of life
  --------------------------------------------------

![Diagnostic Testing for Suspected PAD\
Colors correspond to Class of Recommendation in [Table 1](#T4){ref-type="table"}. ABI indicates ankle-brachial index; CLI, critical limb ischemia; CTA, computed tomography angiography; GDMT, guideline-directed management and therapy; MRA, magnetic resonance angiography; PAD, peripheral artery disease; and TBI, toe-brachial index.](nihms867245f1){#F1}

![Diagnostic Testing for Suspected CLI\
Colors correspond to Class of Recommendation in [Table 1](#T4){ref-type="table"}. \*Order based on expert consensus. †TBI with waveforms, if not already performed. ABI indicates ankle-brachial index; CLI, critical limb ischemia; CTA, computed tomography angiography; MRA, magnetic resonance angiography; TcPO~2~, transcutaneous oxygen pressure; and TBI, toe-brachial index.](nihms867245f2){#F2}

![Diagnosis and Management of ALI\
^[@R21],[@R22]^ Colors correspond to Class of Recommendation in [Table 1](#T4){ref-type="table"}. ALI indicates acute limb ischemia.](nihms867245f3){#F3}

###### ACC/AHA Recommendation System: Applying Class of Recommendation and Level of Evidence to Clinical Strategies, Interventions, Treatments, or Diagnostic Testing in Patient Care[\*](#TFN11){ref-type="table-fn"} (Updated August 2015)

  CLASS (STRENGTH) OF RECOMMENDATION                                                                                                                                                                                                                                                                                                                  
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------
  **Class I (strong)**                                                                                                                                                                                                                                                                                                                                **Benefit \>\>\> Risk**
  Suggested phrases for writing recommendations: ■ Is recommended■ Is indicated/useful/effective/beneficial■ Should be performed/administered/other■ Comparative-Effectiveness Phrases[†](#TFN12){ref-type="table-fn"}: ○ Treatment/strategy A is recommended/indicated in preference to treatment B○ Treatment A should be chosen over treatment B   
  **CLASS IIa (MODERATE)**                                                                                                                                                                                                                                                                                                                            **Benefit \>\> Risk**
  Suggested phrases for writing recommendations; ■ Is reasonable■ Can be useful/effective/beneficial■ Comparative-Effectiveness Phrases[†](#TFN12){ref-type="table-fn"}: ○ Treatment/strategy A is probably recommended/indicated in preference to treatment B○ It is reasonable to choose treatment A over treatment B                               
  **CLASS IIb (WEAK)**                                                                                                                                                                                                                                                                                                                                **Benefit ≥ Risk**
  Suggested phrases for writing recommendations: ■ May/might be reasonable■ May/might be considered■ Usefulness/effectiveness is unknown/unclear/uncertain or not well established                                                                                                                                                                    
  **CLASS III: No Benefit (MODERATE) (*Generally, LOE A or B use only*)**                                                                                                                                                                                                                                                                             **Benefit = Risk**
  Suggested phrases for writing recommendations: ■ Is not recommended■ Is not indicated/useful/effective/beneficial■ Should not be performed/administered/other                                                                                                                                                                                       
  **CLASS III: Harm (STRONG)**                                                                                                                                                                                                                                                                                                                        **Risk \> Benefit**
  Suggested phrases for writing recommendations: ■ Potentially harmful■ Causes harm■ Associated with excess morbidity/mortality■ Should not be performed/administered/other                                                                                                                                                                           
  **LEVEL (QUALITY) OF EVIDENCE**[‡](#TFN13){ref-type="table-fn"}                                                                                                                                                                                                                                                                                     
  **LEVEL A**                                                                                                                                                                                                                                                                                                                                         
  ■ High-quality evidence[‡](#TFN13){ref-type="table-fn"} from more than 1 RCT■ Meta-analyses of high-quality RCTs■ One or more RCTs corroborated by high-quality registry studies                                                                                                                                                                    
  **LEVEL B-R**                                                                                                                                                                                                                                                                                                                                       **(Randomized)**
  ■ Moderate-quality evidence[‡](#TFN13){ref-type="table-fn"} from 1 or more RCTs■ Meta-analyses of moderate-quality RCTs                                                                                                                                                                                                                             
  **LEVEL B-NR**                                                                                                                                                                                                                                                                                                                                      **(Nonrandomized)**
  ■ Moderate-quality evidence[‡](#TFN13){ref-type="table-fn"} from 1 or more well-designed, well-executed nonrandomized studies, observational studies, or registry studies■ Meta-analyses of such studies                                                                                                                                            
  **LEVEL C-LD**                                                                                                                                                                                                                                                                                                                                      **(Limited Data)**
  ■ Randomized or nonrandomized observational or registry studies with limitations of design or execution■ Meta-analyses of such studies■ Physiological or mechanistic studies in human subjects                                                                                                                                                      
  **LEVEL C-E0**                                                                                                                                                                                                                                                                                                                                      **(Expert Opinion)**
  Consensus of expert opinion based on clinical experience                                                                                                                                                                                                                                                                                            

COR and LOE are determined independently (any COR may be paired with any LOE).

A recommendation with LOE C does not imply that the recommendation is weak. Many important clinical questions addressed in guidelines do not lend themselves to clinical trials. Although RCTs are unavailable, there may be a very dear clinical consensus that a particular test or therapy is useful or effective.

The outcome or result of the intervention should be specified (an improved clinical outcome or increased diagnostic accuracy or incremental prognostic information).

For comparative-effectiveness recommendations (COR 1 and lla; LOE A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments or strategies being evaluated.

The method of assessing quality is evolving, including the application of standardized widely used, and preferably validated evidence grading tools; and for systematic reviews, the incorporation of an Evidence Review Committee.

COR indicates Class of Recommendation; EO, expert opinion; LD, limited data; LOE, Level of Evidence; NR, nonrandomized; R, randomized; and RCT randomized controlled trial.

###### Definition of PAD Key Terms

  Term                                                   Definition
  ------------------------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Claudication                                           Fatigue, discomfort, cramping, or pain of vascular origin in the muscles of the lower extremities that is consistently induced by exercise and consistently relieved by rest (within 10 min).
  Acute limb ischemia (ALI)                              Acute (\<2 wk), severe hypoperfusion of the limb characterized by these features: pain, pallor, pulselessness, poikilothermia (cold), paresthesias, and paralysis. One of these categories of ALI is assigned (Section 10): Viable---Limb is not immediately threatened; no sensory loss; no muscle weakness; audible arterial and venous Doppler.Threatened---Mild-to-moderate sensory or motor loss; inaudible arterial Doppler; audible venous Doppler; may be further divided into IIa (marginally threatened) or IIb (immediately threatened).Irreversible---Major tissue loss or permanent nerve damage inevitable; profound sensory loss, anesthetic; profound muscle weakness or paralysis (rigor); inaudible arterial and venous Doppler.^[@R21],[@R22]^
  Tissue loss                                            Type of tissue loss: Minor---nonhealing ulcer, focal gangrene with diffuse pedal ischemia.Major---extending above transmetatarsal level; functional foot no longer salvageable.^[@R21]^
  Critical limb ischemia (CLI)                           A condition characterized by chronic (≥2 wk) ischemic rest pain, nonhealing wound/ulcers, or gangrene in 1 or both legs attributable to objectively proven arterial occlusive disease. The diagnosis of CLI is a constellation of both symptoms and signs. Arterial disease can be proved objectively with ABI, TBI, TcPO~2~, or skin perfusion pressure. Supplementary parameters, such as absolute ankle and toe pressures and pulse volume recordings, may also be used to assess for significant arterial occlusive disease. However, a very low ABI or TBI does not necessarily mean the patient has CLI. The term CLI implies chronicity and is to be distinguished from ALI.^[@R23]^
  In-line blood flow                                     Direct arterial flow to the foot, excluding collaterals.
  Functional status                                      Patient\'s ability to perform normal daily activities required to meet basic needs, fulfill usual roles, and maintain health and well-being. Walking ability is a component of functional status.
  Nonviable limb                                         Condition of extremity (or portion of extremity) in which loss of motor function, neurological function, and tissue integrity cannot be restored with treatment.
  Salvageable limb                                       Condition of extremity with potential to secure viability and preserve motor function to the weight-bearing portion of the foot if treated.
  Structured exercise program                            Planned program that provides individualized recommendations for type, frequency, intensity, and duration of exercise. Program provides recommendations for exercise progression to assure that the body is consistently challenged to increase exercise intensity and levels as functional status improves over time.There are 2 types of structured exercise program for patients with PAD: Supervised exercise programStructured community- or home-based exercise program
  Supervised exercise program                            Structured exercise program that takes place in a hospital or outpatient facility in which intermittent walking exercise is used as the treatment modality. Program can be standalone or can be made available within a cardiac rehabilitation program.Program is directly supervised by qualified healthcare provider(s).Training is performed for a minimum of 30 to 45 min per session, in sessions performed at least 3 times/wk for a minimum of 12 wk.^[@R24]--[@R34]^ Patients may not initially achieve these targets, and a treatment goal is to progress to these levels over time.Training involves intermittent bouts of walking to moderate-to-maximum claudication, alternating with periods of rest.Warm-up and cool-down periods precede and follow each session of walking.
  Structured community- or home-based exercise program   Structured exercise program that takes place in the personal setting of the patient rather than in a clinical setting.^[@R29],[@R35]--[@R39]^ Program is self-directed with the guidance of healthcare providers who prescribe an exercise regimen similar to that of a supervised program.Patient counseling ensures that patients understand how to begin the program, how to maintain the program, and how to progress the difficulty of the walking (by increasing distance or speed).Program may incorporate behavioral change techniques, such as health coaching and/or use of activity monitors.
  Emergency versus urgent                                An *emergency* procedure is one in which life or limb is threatened if the patient is not in the operating room or interventional suite and/or where there is time for no or very limited clinical evaluation, typically within \<6 h.An *urgent* procedure is one in which there may be time for a limited clinical evaluation, usually when life or limb is threatened if the patient is not in the operating room or interventional suite, typically between 6 and 24 h.
  Interdisciplinary care team                            A team of professionals representing different disciplines to assist in the evaluation and management of the patient with PAD. For the care of patients with CLI, the interdisciplinary care team should include individuals who are skilled in endovascular revascularization, surgical revascularization, wound healing therapies and foot surgery, and medical evaluation and care.Interdisciplinary care team members may include: Vascular medical and surgical specialists (ie, vascular medicine, vascular surgery, interventional radiology, interventional cardiology)NursesOrthopedic surgeons and podiatristsEndocrinologistsInternal medicine specialistsInfectious disease specialistsRadiology and vascular imaging specialistsPhysical medicine and rehabilitation cliniciansOrthotics and prosthetics specialistsSocial workersExercise physiologistsPhysical and occupational therapistsNutritionists/dieticians
  Cardiovascular ischemic events                         Acute coronary syndrome (acute MI, unstable angina), stroke, or cardiovascular death.
  Limb-related events                                    Worsening claudication, new CLI, new lower extremity revascularization, or new ischemic amputation.

ABI indicates ankle-brachial index; ALI, acute limb ischemia; CLI, critical limb ischemia; MI, myocardial infarction; PAD, peripheral artery disease; TBI, toe-brachial index; and TcPO~2~, transcutaneous oxygen pressure.

###### Patients at Increased Risk of PAD

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Age ≥65 y
  Age 50--64 y, with risk factors for atherosclerosis (eg, diabetes mellitus, history of smoking, hyperlipidemia, hypertension) or family history of PAD^[@R52]^
  Age \<50 y, with diabetes mellitus and 1 additional risk factor for atherosclerosis
  Individuals with known atherosclerotic disease in another vascular bed (eg, coronary, carotid, subclavian, renal, mesenteric artery stenosis, or AAA)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------

AAA indicates abdominal aortic aneurysm; PAD, peripheral artery disease.

###### History and/or Physical Examination Findings Suggestive of PAD

  ---------------------------------------------------------------------------------------------
  History
   Claudication
   Other non--joint-related exertional lower extremity symptoms (not typical of claudication)
   Impaired walking function
   Ischemic rest pain
  Physical Examination
   Abnormal lower extremity pulse examination
   Vascular bruit
   Nonhealing lower extremity wound
   Lower extremity gangrene
   Other suggestive lower extremity physical findings (eg, elevation pallor/dependent rubor)
  ---------------------------------------------------------------------------------------------

PAD indicates peripheral artery disease.

###### Alternative Diagnoses for Leg Pain or Claudication With Normal Physiological Testing (Not PAD-Related)

  Condition                      Location                                  Characteristic           Effect of Exercise                         Effect of Rest                                        Effect of Position                      Other Characteristics
  ------------------------------ ----------------------------------------- ------------------------ ------------------------------------------ ----------------------------------------------------- --------------------------------------- -----------------------------------------------------------------------------
  Symptomatic Baker\'s cyst      Behind knee, down calf                    Swelling, tenderness     With exercise                              Also present at rest                                  None                                    Not intermittent
  Venous claudication            Entire leg, worse in calf                 Tight, bursting pain     After walking                              Subsides slowly                                       Relief speeded by elevation             History of iliofemoral deep vein thrombosis; edema; signs of venous stasis
  Chronic compartment syndrome   Calf muscles                              Tight, bursting pain     After much exercise (jogging)              Subsides very slowly                                  Relief with rest                        Typically heavy muscled athletes
  Spinal stenosis                Often bilateral buttocks, posterior leg   Pain and weakness        May mimic claudication                     Variable relief but can take a long time to recover   Relief by lumbar spine flexion          Worse with standing and extending spine
  Nerve root compression         Radiates down leg                         Sharp lancinating pain   Induced by sitting, standing, or walking   Often present at rest                                 Improved by change in position          History of back problems; worse with sitting; relief when supine or sitting
  Hip arthritis                  Lateral hip, thigh                        Aching discomfort        After variable degree of exercise          Not quickly relieved                                  Improved when not weight bearing        Symptoms variable; history of degenerative arthritis
  Foot/ankle arthritis           Ankle, foot, arch                         Aching pain              After variable degree of exercise          Not quickly relieved                                  May be relieved by not bearing weight   Symptoms variable; may be related to activity level or present at rest

Modified from Norgren L et al.^[@R23]^

PAD indicates peripheral artery disease.

###### Alternative Diagnoses for Nonhealing Wounds With Normal Physiological Testing (Not PAD-Related)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Condition                                           Location                                       Characteristics and Causes
  --------------------------------------------------- ---------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Venous ulcer                                        Distal leg, especially above medial mellolus   Develops in regions of skin changes due to chronic venous disease and local venous hypertension Typically wet (ie, wound drainage) rather than dry lesion

  Distal small arterial occlusion (microangiopathy)   Toes, foot, leg                                End-stage renal disease\
                                                                                                     Thromboangiitis obliterans (Buerger\'s)\
                                                                                                     Sickle-cell anemia\
                                                                                                     Vasculitis (eg, Churg-Strauss, Henoch-Schonlein purpura, leukocytoclastic vasculitis, microscopic polyangiitis, polyarteritis nodosa)\
                                                                                                     Scleroderma\
                                                                                                     Cryoagglutination\
                                                                                                     Embolic (eg, cholesterol emboli, thromboemboli, endocarditis)\
                                                                                                     Thrombotic (eg, antiphospholipid antibody syndrome, Sneddon\'s syndrome, warfarin skin necrosis, disseminated intravascular coagulation, livedoid vasculitis, protein C or S deficiency, prolonged vasospasm)

  Local injury                                        Toes, foot, leg                                Trauma\
                                                                                                     Insect or animal bite\
                                                                                                     Burn

  Medication related                                  Toes, foot, leg                                Drug reactions (eg, erythema multiforme)\
                                                                                                     Medication direct toxicity (eg, doxorubicin, hydroxyurea, some tyrosine kinase inhibitors)

  Neuropathic                                         Pressure zones of foot                         Hyperkeratosis surrounds the ulcer\
                                                                                                     Diabetes mellitus with peripheral neuropathy\
                                                                                                     Peripheral neuropathy without diabetes mellitus\
                                                                                                     Leprosy

  Autoimmune injury                                   Toes, foot, leg                                With blisters (eg, pemphigoid, pemphigus, epidermolysis bullosa)\
                                                                                                     Without blisters (eg, dermatomyositis, lupus, scleroderma)

  Infection                                           Toes, foot, leg                                Bacterial (eg, pseudomonas, necrotizing streptococcus)\
                                                                                                     Fungal (eg, blastomycosis, Madura foot, chromomycosis)\
                                                                                                     Mycobacterial\
                                                                                                     Parasitic (eg, Chagas, leishmaniasis)\
                                                                                                     Viral (eg, herpes)

  Malignancy                                          Toes, foot, leg                                Primary skin malignancy\
                                                                                                     Metastatic malignancy\
                                                                                                     Malignant transformation of ulcer

  Inflammatory                                        Toes, foot, leg                                Necrobiosis lipoidica\
                                                                                                     Pyoderma gangrenosum\
                                                                                                     Granuloma annulare
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PAD indicates peripheral artery disease.

###### Structured Exercise Programs for PAD: Definitions

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Supervised exercise program (COR I, LOE A)
   Program takes place in a hospital or outpatient facility.
   Program uses intermittent walking exercise as the treatment modality.
   Program can be standalone or within a cardiac rehabilitation program.
   Program is directly supervised by qualified healthcare provider(s).
   Training is performed for a minimum of 30--45 min/session; sessions are performed at least 3 times/wk for a minimum of 12 wk.^[@R24]--[@R34]^
   Training involves intermittent bouts of walking to moderate-to-maximum claudication, alternating with periods of rest.
   Warm-up and cool-down periods precede and follow each session of walking.
  Structured community- or home-based exercise program (COR IIa, LOE A)
   Program takes place in the personal setting of the patient rather than in a clinical setting.^[@R29],[@R35]--[@R39]^
   Program is self-directed with guidance of healthcare providers.
   Healthcare providers prescribe an exercise regimen similar to that of a supervised program.
   Patient counseling ensures understanding of how to begin and maintain the program and how to progress the difficulty of the walking (by increasing distance or speed).
   Program may incorporate behavioral change techniques, such as health coaching or use of activity monitors.
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------

COR indicates Class of Recommendation; LOE, Level of Evidence; and PAD, peripheral artery disease.

###### Interdisciplinary Care Team for PAD

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  A team of professionals representing different disciplines to assist in the evaluation and management of the patient with PAD. For the care of patients with CLI, the interdisciplinary care team should include individuals who are skilled in endovascular revascularization, surgical revascularization, wound healing therapies and foot surgery, and medical evaluation and care.
  Interdisciplinary care team members may include:
  Vascular medical and surgical specialists (ie, vascular medicine, vascular surgery, interventional radiology, interventional cardiology)
   Nurses
   Orthopedic surgeons and podiatrists
   Endocrinologists
   Internal medicine specialists
   Infectious disease specialists
   Radiology and vascular imaging specialists
   Physical medicine and rehabilitation clinicians
   Orthotics and prosthetics specialists
   Social workers
   Exercise physiologists
   Physical and occupational therapists
   Nutritionists/dieticians
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CLI indicates critical limb ischemia; and PAD, peripheral artery disease.

###### Therapy for CLI: Findings That Prompt Consideration of Surgical or Endovascular Revascularization

  Findings That Favor Consideration of Surgical Revascularization                                                                                                                                                                      Examples
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
   Factors associated with technical failure or poor durability with endovascular treatment                                                                                                                                            Lesion involving common femoral artery, including origin of deep femoral artery
  Long segment lesion involving the below-knee popliteal and/or infrapopliteal arteries in a patient with suitable single-segment autogenous vein conduit                                                                              
  Diffuse multilevel disease that would require endovascular revascularization at multiple anatomic levels                                                                                                                             
  Small-diameter target artery proximal to site of stenosis or densely calcified lesion at location of endovascular treatment                                                                                                          
   Endovascular treatment likely to preclude or complicate subsequent achievement of in-line blood flow through surgical revascularization                                                                                             Single-vessel runoff distal to ankle
  Findings That Favor Consideration of Endovascular Revascularization                                                                                                                                                                  Examples
   The presence of patient comorbidities may place patients at increased risk of perioperative complications from surgical revascularization. In these patients, an endovascular-first approach should be used regardless of anatomy   Patient comorbidities, including coronary ischemia, cardiomyopathy, congestive heart failure, severe lung disease, and chronic kidney disease
   Patients with rest pain and disease at multiple levels may undergo a staged approach as part of endovascular-first approach                                                                                                         In-flow disease can be addressed first, and out-flow disease can be addressed in a staged manner, when required, if clinical factors or patient safety prevent addressing all diseased segments at one setting
   Patients without suitable autologous vein for bypass grafts                                                                                                                                                                         Some patients have had veins harvested for previous coronary artery bypass surgery and do not have adequate remaining veins for use as conduits. Similarly, patients may not have undergone prior saphenous vein harvest, but available vein is of inadequate diameter

CLI indicates critical limb ischemia.

[^1]: Developed in Collaboration With the American Association of Cardiovascular and Pulmonary Rehabilitation, Inter-Society Consensus for the Management of Peripheral Arterial Disease, Society for Cardiovascular Angiography and Interventions, Society for Clinical Vascular Surgery, Society of Interventional Radiology, Society for Vascular Medicine, Society for Vascular Nursing, Society for Vascular Surgery, and Vascular and Endovascular Surgery Society
